京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第20053号 / 医博第4161号 / 新制||医||1018(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 古川 壽亮, 教授 佐藤 俊哉, 教授 村井 俊哉 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第20800号 / 医博第4300号 / 新制||医||1025(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 武藤 学, 教授 福原 俊一, 教授 福田 和彦 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Over one third of breast cancer survivors report “fear of recurrence” as the primary concern after diagnosis and treatment. Behavior changes such as exercise and weight loss post cancer may reduce recurrence risk. How perceived recurrence risk affects behavior change is unknown. We evaluated this association in the Breast Cancer Survivorship Study, a cross-sectional study of 301 breast cancer survivors. Data on perceived recurrence risk (local and distant) and health behavior change (alcohol, exercise, nutrition, smoking, sun exposure, supplement use, weight) were assessed by mailed questionnaire. Multivariable logistic regressions were used to evaluate associations between perceived recurrence risk and health behavior change, and multinomial logistic regression to assess direction of change. 47.6% of women perceived their local recurrence risk <10%, while 36.3% perceived distant between 10-30%. Participants mean age was 60 years and had predominantly early stage cancer. Over 90% of women reported making a behavior change. Significant associations were found between higher perceived recurrence risk and behavior changes of nutrition (OR 3.1, 95% CI 1.6-6.3) and sun exposure (OR 2.5, 95% CI 1.2- 5.0). Exploratory direction of change analyses found women with higher perceived recurrence risk were more likely to make positive changes in nutrition (OR 4.0, 95% CI 1.9-8.2) and sun exposure (OR 2.5, 95% CI 1.2-5.2). Overall, we found trends that women are likely to make specific behavior changes as their perceived recurrence risk increases. Findings provide a baseline for future research to identify survivors more likely to make behavior changes that affect their long term health.

No description available.

Considered the most common malignancy in women in the United States and second leading cause of cancer death among women, breast cancer has had a shift in paradigm of treatment within the recent years and undertaken significant research for new targeted treatment with a more molecular driven approach which has led to increased survival rates amongst women diagnosed with early stage breast cancer. The risk of recurrence however persists overtime, particularly in hormone receptor positive breast cancer, which has demonstrated recurrence rates as late as 30 years after initial diagnosis. This leads to a higher need for increased awareness of late recurrence rates in early stage breast cancer patients and reminds us to be wary of any new findings that in other patients may be considered as benign. We present a case of a 67-year-old female with remote history of locally advanced hormone positive breast cancer in 2005 who underwent mastectomy with lymph node dissection followed by adjuvant chemotherapy, radiation, and endocrine therapy for at least 8 years who presented to our clinic 18 years after initial diagnosis with an enlarging nodule in her neck. Patient underwent a thyroid ultrasound which showed a suspicious thyroid nodule concerning for malignancy classified as TIRADS-5. Further systemic imaging via PET-Scan demonstrated surrounding cervical lymphadenopathy adjacent to the thyroid nodule with increased fluorodeoxyglucose (FDG) avidity. She proceeded to undergo a thyroid fine needle biopsy, which was suspicious for malignancy. A repeat thyroid fine needle biopsy was obtained this time confirming metastatic breast cancer. Considering the rarity of such event, we proceeded with further testing of biopsied tissue via cancer type ID, which confirmed presence of metastatic breast cancer in the thyroid. Patient was informed of now metastatic breast cancer diagnosis with plans to start Faslodex and Ibrance. Unfortunately, she developed rapid disease progression with hospitalization due to a recurrent malignant pericardial effusion suggestive of visceral crisis requiring initiation on palliative chemotherapy with Carboplatin and Gemcitabine. Patient has been tolerating systemic chemotherapy well with interval clinical decrease of more than 50% in size of her surrounding cervical lymphadenopathy and resolution of pericardial effusion. The incidence of thyroid metastatic disease from breast cancer is very rare accounting for only 0.2% of fine needle biopsy aspirations. The most common sites of breast cancer metastasis include lung, bone, liver, and brain. On the other hand, the most common primary malignancies that can cause metastasis to the thyroid are kidney, gastrointestinal tract, and lung. However, as of 2018 around 42 cases of metastatic breast cancer found in the thyroid had been reported and it was also noted that metastatic thyroid involvement of breast cancer could be associated with a poor prognosis. This case represents the importance of being aware of the risk of late recurrence in hormone positive breast cancers, which in turn should result in a lower threshold for thorough workup of common clinical findings in these patients.

No description available.

No description available.

No description available.

No description available.

No description available.